387 related articles for article (PubMed ID: 29610002)
1. Renal Cell Carcinoma Presenting as Carcinoma of Unknown Primary Site: Recognition of a Treatable Patient Subset.
Greco FA; Hainsworth JD
Clin Genitourin Cancer; 2018 Aug; 16(4):e893-e898. PubMed ID: 29610002
[TBL] [Abstract][Full Text] [Related]
2. Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay.
Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
Mol Diagn Ther; 2015 Apr; 19(2):91-7. PubMed ID: 25758902
[TBL] [Abstract][Full Text] [Related]
3. Role of Molecular Profiling in Diagnosis of Papillary Renal-cell Cancer Presenting as Cancer of Unknown Primary Site.
Nagasaka M; Kukreja G; Abdulfatah E; Vaishampayan U; Sukari A
Clin Genitourin Cancer; 2017 Aug; 15(4):e713-e717. PubMed ID: 28024951
[No Abstract] [Full Text] [Related]
4. Incidence of Clear Cell Papillary Renal Cell Carcinoma in Low-Grade Renal Cell Carcinoma Cases: A 12-Year Retrospective Clinicopathologic Study From a Single Cancer Center.
Gill S; Kauffman EC; Kandel S; George S; Schwaab T; Xu B
Int J Surg Pathol; 2016 May; 24(3):207-12. PubMed ID: 26510859
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.
Hainsworth JD; Greco FA
Virchows Arch; 2014 Apr; 464(4):393-402. PubMed ID: 24487792
[TBL] [Abstract][Full Text] [Related]
6. Role Of Immunohistochemistry In Subtyping Renal Cell Carcinomas With Overlapping Morphological Features.
Tariq N; Mamoon N; Haroon A; Ali Z; Ahmad IN
J Ayub Med Coll Abbottabad; 2018; 30(3):325-332. PubMed ID: 30465359
[TBL] [Abstract][Full Text] [Related]
7. Molecular-genetic analysis is essential for accurate classification of renal carcinoma resembling Xp11.2 translocation carcinoma.
Hayes M; Peckova K; Martinek P; Hora M; Kalusova K; Straka L; Daum O; Kokoskova B; Rotterova P; Pivovarčikova K; Branzovsky J; Dubova M; Vesela P; Michal M; Hes O
Virchows Arch; 2015 Mar; 466(3):313-22. PubMed ID: 25544614
[TBL] [Abstract][Full Text] [Related]
8. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.
Varadhachary GR; Talantov D; Raber MN; Meng C; Hess KR; Jatkoe T; Lenzi R; Spigel DR; Wang Y; Greco FA; Abbruzzese JL; Hainsworth JD
J Clin Oncol; 2008 Sep; 26(27):4442-8. PubMed ID: 18802157
[TBL] [Abstract][Full Text] [Related]
9. GATA3 as a valuable marker to distinguish clear cell papillary renal cell carcinomas from morphologic mimics.
Mantilla JG; Antic T; Tretiakova M
Hum Pathol; 2017 Aug; 66():152-158. PubMed ID: 28705707
[TBL] [Abstract][Full Text] [Related]
10. Renal Neoplasms With Overlapping Features of Clear Cell Renal Cell Carcinoma and Clear Cell Papillary Renal Cell Carcinoma: A Clinicopathologic Study of 37 Cases From a Single Institution.
Dhakal HP; McKenney JK; Khor LY; Reynolds JP; Magi-Galluzzi C; Przybycin CG
Am J Surg Pathol; 2016 Feb; 40(2):141-54. PubMed ID: 26752401
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology.
Motzer RJ; Bacik J; Mariani T; Russo P; Mazumdar M; Reuter V
J Clin Oncol; 2002 May; 20(9):2376-81. PubMed ID: 11981011
[TBL] [Abstract][Full Text] [Related]
12. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.
Hainsworth JD; Rubin MS; Spigel DR; Boccia RV; Raby S; Quinn R; Greco FA
J Clin Oncol; 2013 Jan; 31(2):217-23. PubMed ID: 23032625
[TBL] [Abstract][Full Text] [Related]
13. Pediatric renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions and clinicopathologic associations.
Altinok G; Kattar MM; Mohamed A; Poulik J; Grignon D; Rabah R
Pediatr Dev Pathol; 2005; 8(2):168-80. PubMed ID: 15747097
[TBL] [Abstract][Full Text] [Related]
14. Vascular cell adhesion molecule 1 predicts cancer-free survival in clear cell renal carcinoma patients.
Shioi K; Komiya A; Hattori K; Huang Y; Sano F; Murakami T; Nakaigawa N; Kishida T; Kubota Y; Nagashima Y; Yao M
Clin Cancer Res; 2006 Dec; 12(24):7339-46. PubMed ID: 17189405
[TBL] [Abstract][Full Text] [Related]
15. Expression of parafibromin in clear cell papillary renal cell carcinoma.
Cui C; Ziober A; Bing Z
Appl Immunohistochem Mol Morphol; 2013 Jul; 21(4):322-5. PubMed ID: 23060304
[TBL] [Abstract][Full Text] [Related]
16. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology.
Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
J Natl Cancer Inst; 2013 Jun; 105(11):782-90. PubMed ID: 23641043
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical Panel for Differentiating Renal Cell Carcinoma with Clear and Papillary Features.
Alshenawy HA
Pathol Oncol Res; 2015 Sep; 21(4):893-9. PubMed ID: 25712789
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide gene expression profiles of clear cell renal cell carcinoma: identification of molecular targets for treatment of renal cell carcinoma.
Hirota E; Yan L; Tsunoda T; Ashida S; Fujime M; Shuin T; Miki T; Nakamura Y; Katagiri T
Int J Oncol; 2006 Oct; 29(4):799-827. PubMed ID: 16964377
[TBL] [Abstract][Full Text] [Related]
19. Proteomic identification of Reticulocalbin 1 as potential tumor marker in renal cell carcinoma.
Giribaldi G; Barbero G; Mandili G; Daniele L; Khadjavi A; Notarpietro A; Ulliers D; Prato M; Minero VG; Battaglia A; Allasia M; Bosio A; Sapino A; Gontero P; Frea B; Fontana D; Destefanis P
J Proteomics; 2013 Oct; 91():385-92. PubMed ID: 23916412
[TBL] [Abstract][Full Text] [Related]
20. [Cancer of unknown primary-The new ESMO guidelines].
Bochtler T; Pouyiourou M; Krämer A
Radiologie (Heidelb); 2023 May; 63(5):329-335. PubMed ID: 36930265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
